Merck

View All

Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) – Market Is Expected to Grow with Upcoming Therapies

Systemic Lupus Erythematosus (SLE) is a chronic, multisystem, inflammatory autoimmune disease which leads to weakening of the immune system. It results in systemic inflammation which affects multiple organs such as kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain. Acute Cutaneous Lupus, ...

Find More

Notizia
Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval

Another flop for Alzeimer’s as Late Stage drug of AxovantSciences fails in trial Axovant Sciences has reported the failure of their late-stage trial involving the testing of its pill Intepirdinecould not suppress Alzheimer's symptoms in participants of the trail. The news had plunged the Wall Street into another wav...

Find More

Human Papillomavirus (HPV) Prophylaxis– Expected to see a steady growth from 2015-2025

A total of approximately 7.3 Million people were vaccinated with HPV vaccines in 2016, as per the latest report of DelveInsight. Human Papillomavirus is a double stranded DNA virus that infects squamous epithelia including the skin and mucosae of the upper respiratory and anogenital tracts. HPV is a group of more th...

Find More

Entasis
CAR-T Phase I trials; ContraVir Announces; Merck acquired; Excision BioTherapeutics bags $10M

Two ongoing CAR-T Phase I trials of Cellectis drug candidate has been put on hold by FDA after a patient’s death FDA has put two CAR-T trials on hold following a patient’s death, less than a week after the first ever CAR-T was approved by the US regulatory agency.  The patient (78) was suffering from r...

Find More

Personalized Medicine
Allergan sell; AZ, Merck team up; Roche’s MS drug; Chinese API maker receives a warning letter

Allergan can finally sell its losing stake in Teva. Will it? Allergan, which acquired a 9.9% stake in the Israeli drugmaker last year as part of the pair’s $40 billion-plus generics deal, currently stands as Teva’s largest shareholder. Those shares, worth $5.3 billion when Allergan acquired them, have been locked do...

Find More

Remicade’s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project

Samsung and Merck launch Remicade biosim at 35% discount After the first biosimilar of Johnson & Johnson’s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with a much deeper pricing slash. Samsung and marketing partner Merck & Co. Monday launched the...

Find More

Personalized Medicine
Merck got attack; Stada’s €5.32B; Private equity fund buys; Lonza on $5.5B deal

Merck targeted in global ransomware attack Merck & Co. was among those affected by a massive ransomware attack Tuesday that infiltrated the computer systems of companies around the world as well as government ministries in Ukraine. Merck confirmed in Twitter posts Tuesday that it was hit in the cyberattack but d...

Find More

Personalized Medicine
Merck’s Remicade; Sanofi, Regeneron set Kevzara; Novartis to sever; Teva puts women’s health

Merck's Remicade discounting put squeeze on biosims—and broke U.K. law, officials say Under biosimilar assault in Europe, Merck rolled out cut-rate deals on Remicade to defend its brand from cheaper options, then-brand-new to the market. Now, the U.K.’s competition authority claims the pharma giant “broke competitio...

Find More

Therapeutics
Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal

Merck beats Q1 estimates as Keytruda sales double Merck is the victim of its own success, judging from its first-quarter report. The company beat sales and earnings estimates, and it upped its guidance for the year, despite some significant suffering from generic competition. Sales of its hit immuno-oncology drug Ke...

Find More

Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A

Merck sells biosimilars business to Fresenius Merck has divested its biosimilars business to fellow German drug maker Fresenius in a deal potentially worth 670 million euros. The drug maker said the move is aligned with a strategy of focusing on innovative medicines while enabling it to exploit its biosimilars portf...

Find More